Skip to main content
SpringerLink
Log in

Drug-Induced Antinuclear Antibodies and Lupus Syndromes

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Drugs capable of triggering the onset of systemic lupus erythematosus may be divided into those that do so by pharmacological properties of their own and those that do so by eliciting allergic reactions which bring about lupus.

Drugs in the first group vary in their potency to activate lupus. They all elicit antinuclear antibodies in the majority of patients who receive them but they only cause lupus in a small percentage of patients. This dichotomy suggests that a predisposition is required for the development of lupus upon intake of these drugs.

The mechanism whereby these drugs elicit antinuclear antibodies seems to relate to coupling to and/or modification of nuclear antigens. The patterns of antinuclear antibodies elicited by these drugs in individuals who receive them correlate well with their known reactivity with various nuclear antigens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alarcón-Segovia, D.: Drug-induced lupus syndromes. Mayo Clinic Proceedings 44: 664–681 (1969).

    PubMed  Google Scholar 

  • Alarcón-Segovia, D.: Acute immunologic hydralazine reaction. Clinical and serological changes after hydralazine administration to a patient with circulating anti-nuclear antibodies. Revista de Investigación Clínica, México 24: 167–174 (1972).

    Google Scholar 

  • Alarcón-Segovia, D. and Fishbein, E.: Patterns of anti-nuclear antibodies and lupus-activating drugs. Journal of Rheumatology 2: 167–171 (1975).

    PubMed  Google Scholar 

  • Alarcón-Segovia, D.; Fishbein, E. and Alcala, H.: Isoniazid acetylation rate and development of antinuclear antibodies upon isoniazid treatment. Arthritis and Rheumatism 14: 748–752 (1971).

    Article  PubMed  Google Scholar 

  • Alarcón-Segovia, D.; Fishbein, E. and Betancourt, V.M.: Antibodies to nucleoprotein and to hydrazide-altered soluble nucleoprotein in tuberculous patients receiving isoniazid. Clinical and Experimental Immunology 5: 429–437 (1969).

    PubMed  Google Scholar 

  • Alarcón-Segovia, D.; Fishbein, E.; Cetina, J.A.; Raya, R.J. and Barrera, E.: Antigenic specificity of chlorpromazine-induced antinuclear antibodies. Clinical and Experimental Immunology 15: 543–548 (1973).

    PubMed  Google Scholar 

  • Alarcón-Segovia, D.; Fishbein, E.; Reyes, P.A.; Díes, H. and Schwadsky, S.: Antinuclear antibodies in patients on anticonvulsant therapy. Clinical and Experimental Immunology 12: 39–47 (1972).

    PubMed  Google Scholar 

  • Alarcón-Segovia, D.; Wakim, K.G.; Worthington, J.W. and Ward, L.E.: Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus. Medicine (Baltimore) 46: 1–33 (1967).

    Article  Google Scholar 

  • Alarcón-Segovia, D.; Worthington, J.W.; Ward, L.E. and Wakim, K.G.: Lupus diathesis and the hydralazine syndrome. New England Journal of Medicine 272: 462–466 (1965).

    Article  PubMed  Google Scholar 

  • Bendersky, G. and Ramirez, C.: Hydralazine poisoning. Review of the literature and autopsy study of person with massive intestinal bleeding. Journal of the American Medical Association 173: 1789–1794 (1960).

    CAS  Google Scholar 

  • Blomgren, S.E.; Condemi, J.J. and Vaughan, J.H.: Procainamide induced lupus erythematosus. Clinical and laboratory observations. American Journal of Medicine 52: 338–348 (1972).

    CAS  Google Scholar 

  • Byrd, R.B. and Schanzer, B.: Pulmonary sequelae in procaine amide induced lupus-like syndrome. Diseases of the Chest 55: 170–172(1969).

    Article  PubMed  CAS  Google Scholar 

  • Cannat, A. and Seligmann, M.: Induction by isoniazid and hydralazine of antinuclear factors in mice. Clinical and Experimental Immunology 3: 99–105 (1968).

    PubMed  CAS  Google Scholar 

  • Carstairs, K.C.; Breckenridge, A.; Dollerey, C.T. and Worlledge, S.M.: Incidence of a positive direct Coombs test in patients on α-Methyldopa. Lancet 2: 133–135 (1966).

    Article  PubMed  CAS  Google Scholar 

  • Cetina, J.A.; Fishbein, E. and Alarcón-Segovia, D.: Antinuclear antibodies and propylthiouracil therapy. Journal of the American Medical Association 220: 1012 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Comens, P.: Experimental hydralazine disease and its similarity to disseminated lupus erythematosus. Journal of Laboratory and Clinical Medicine 47: 444–454 (1956).

    PubMed  CAS  Google Scholar 

  • Dammin, G.J.; Nora, J.R. and Reardan, J.B.: Hydralazine reaction: case with LE cells antemortem and postmortem study and pulmonary, renal, splenic and muscular lesions of disseminated lupus erythematosus. Journal of Laboratory and Clinical Medicine 46: 806 (1955).

    Google Scholar 

  • Delepierre, F.; Rulliere, R. and Coury, C.H.: Syndromes lupiques et apparentés: complication réputée rare des traitements prologés par l’isoniazide et autres médicaments antituberculeux (a propos de deux nouvelles observations). Revue de Tuberculose et de Pneumologie 35: 397–412 (1971).

    PubMed  CAS  Google Scholar 

  • Domz, C.A.; McNamara, D.H. and Holzpfel, H.F.: Tetracycline provocation in lupus erythematosus. Annals of Internal Medicine 50: 1217–1226 (1959).

    PubMed  CAS  Google Scholar 

  • Dubois, E.L.: The clinical picture of systemic lupus erythematosus chapter 9, supplement 1; in Dupois (Ed) Lupus Erythematosus. A Review of the Current Status of Discoid and Systemic Lupus Erythematosus and their Variants, p. 38–438 (University of Southern California Press, Los Angeles 1974).

    Google Scholar 

  • Dubois, E.L.; Molina, J.; Bilitch, M. and Friou, G.J.: Procainamide-induced serologic changes in asymptomatic patients. Arthritis and Rheumatism 11: 477–478 (1968).

    Google Scholar 

  • Dubois, E.L. and Tuffanelli, D.L.: Clinical manifestations of systemic lupus erythematosus: Computer analysis of 520 cases. Journal of the American Medical Association 190: 104–111 (1964).

    Article  PubMed  CAS  Google Scholar 

  • Dustan, H.P.; Taylor, R.D.; Corcoran, A.C. and Page, I.H.: Rheumatic and febrile syndrome during prolonged hydralazine treatment. Journal of the American Medical Association 154: 23–29 (1954).

    Article  PubMed  CAS  Google Scholar 

  • Eldredge, N.T.; Robertson, W. Van B. and Miller, J.J. III: The interaction of lupus-inducing drugs with deoxyribonucleic acid.ClinicalImmunology and Immunopathology 3: 263–271 (1974).

    Article  CAS  Google Scholar 

  • Fakhro, A.M.; Ritchie, R.F. and Lown, B.: Lupus-like syndrome induced by procainamide. American Journal of Cardiology 20: 367–373 (1967).

    Article  PubMed  CAS  Google Scholar 

  • Feltkamp, T.E.W.; Dorhout Mees, E.J. and Nieuwenhuis, M.G.: Auto antibodies related to treatment with chlorthalidone and α-methyldopa. Acta Medica Scandinavica 187: 219–223 (1970).

    Article  PubMed  CAS  Google Scholar 

  • Fishbein, E. and Alarcón-Segovia, D.: Actividad de acetil transferasa hepática. Un marcador genético del lupus eritematoso generalizado. Memorias VII Congreso Mexicano de Reumatología, Mexico City, Mexico, p.32 (1976).

    Google Scholar 

  • Grob, P.J.; Müller-Schoop, J.W.; Häcki, M.A. and Joller-Jemelka, H.I.: Drug-induced pseudolupus. Lancet 2: 144–148 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Hahn, B.H.; Sharp, G.C.; Irvin, W.S.; Kantor, O.S.; Gardner, C.A.; Bagby, M.K.; Perry, H.M. and Osterland, C.K.: Immune responses to hydralazine and nuclear antigens in hydralazine-induced lupus erythematosus. American Journal of Medicine 76: 365–374 (1972).

    CAS  Google Scholar 

  • Hildreth, E.A.; Biro, C.E. and McCreary, T.A.: Persistence of the ‘hydralazine syndrome’: a follow-up study of eleven cases. Journal of the American Medical Association 173: 657–660 (1960).

    Article  Google Scholar 

  • Holley, H.L.: Evidence for a predisposition to rheumatic diseases in families of patients developing drug-induced systemic lupus erythematosus. Arthritis and Rheumatism 7: 684–686 (1964).

    Article  PubMed  CAS  Google Scholar 

  • Kahn, G. and Davis, B.P.: In vitro studies on longwave ultraviolet light-dependent reactions of the skin photosensitizer chlorpromazine with nucleic acids, purines and pyrimidines. Journal of Investigative Dermatology 55: 47–52 (1970).

    Article  PubMed  CAS  Google Scholar 

  • Lappat, E.J. and Cawein, M.J.: A familial study of procainamide-induced systemic lupus erythematosus: a question of pharmacogenetic polymorphism. American Journal of Medicine 45: 846–852 (1968).

    Article  PubMed  CAS  Google Scholar 

  • Lee, S.L.; Rivero, I. and Siegel, M.: Activation of systemic lupus erythematosus by drugs. Archives of Internal Medicine 117: 620–626 (1966).

    Article  PubMed  CAS  Google Scholar 

  • Meislin, A.G. and Rothfield, N.: Systemic lupus erythematosus in childhood: analysis of 42 cases with comparative data in 200 adult cases followed concurrently. Pediatrics 42: 37–49 (1968).

    PubMed  CAS  Google Scholar 

  • Monier, J.C.: Collagenose posthydralazinique chez le rat. Algérie Medicale 64: 421–426 (1960).

    PubMed  CAS  Google Scholar 

  • Muller, J.C.; Rast, C.L. Jr.; Pryor, W.W. and Orgain, E.S.: Late systemic complication of hydralazine (Apresoline) therapy. Journal of the American Medical Association 157: 894–899 (1955).

    Article  PubMed  CAS  Google Scholar 

  • Notwan, D.D.; Kurata, N. and Tan, E.M.: Profiles of antinuclear antibodies in systemic rheumatic diseases. Annals of Internal Medicine 83: 464–469 (1975).

    Google Scholar 

  • Novack, M.A. and Paine, R.: Procainamide-induced lupus syndrome in siblings. Journal of the American Medical Association 232: 1269 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Ohnishi, S. and McConnel, H.M.: Interaction of the radical ion of chlorpromazine with deoxyribonucleic acid. Journal of the American Chemical Society 87: 2293–2296 (1965).

    Article  PubMed  CAS  Google Scholar 

  • Paine, R.: Procainamide hydrochloride and lupus erythematosus. Journal of the American Medical Association 194: 23–26 (1965).

    Article  PubMed  CAS  Google Scholar 

  • Perry, H.M. Jr. and Schroeder, H.A.: Syndrome simulating collagen disease caused by hydralazine (Apresoline). Journal of the American Medical Association 154: 670–673 (1954).

    Article  PubMed  Google Scholar 

  • Perry, H.M. Jr.; Tan, E.M.; Carmody, S. and Sakamoto, A.: Relationship of acetil transferase activity to anti-nuclear antibodies and toxic symptoms in hypertensive patients treated with hydrallazine. Journal of Laboratory and Clinical Medicine 76: 114–125 (1970).

    PubMed  Google Scholar 

  • Price Evans, D.A.; Bullen, M.F.; Houston, J.; Hopkins, C.A. and Vetters, J.M.: Antinuclear factors in rapid and slow acetylators patients treated with isoniazid. Journal of Medical Genetics 9: 53–56 (1972).

    Article  Google Scholar 

  • Quismorio, F.P.; Bjarnasson, D.F.; Dubois, E.L. and Friou, G.J.: Chlorpromazine-induced antinuclear antibodies. Arthritis and Rheumatism 15: 451 (1972).

    Google Scholar 

  • Rallison, M.L.; O’Brien, J. and Good, R.A.: Severe reactions to long-acting sulfonamides: erythema multi-forme exudativum and lupus erythematosus following administration of sulfamethoxypyridazine and sulfa-dimethoxine. Pediatrics 28: 908–917 (1961).

    PubMed  CAS  Google Scholar 

  • Reidenberg, M.M. and Martin, J.H.: The acetylator phenotype of patients with systemic lupus erythematosus. Drug Metabolism and Disposition 2: 71–73 (1974).

    PubMed  CAS  Google Scholar 

  • Reza, M.D.; Dornfeld, L. and Goldberg, L.S.: Hydralazine therapy in hypertensive patients with idiopathic systemic lupus erythematosus. Arthritis and Rheumatism 18: 335–338 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Rupe, C.E. and Nickel, S.N.: New clinical concept of systemic lupus erythematosus: analysis of 100 cases. Journal of the American Medical Association 171: 1055–1061 (1959).

    Article  PubMed  CAS  Google Scholar 

  • Sharp, G.C.; Irvin, W.S.; Tan, E.M. and Holman, H.R.: Mixed connective tissue disease — An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). American Journal of Medicine 52: 148–159 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Shulman, L.E.: Inducing agents and relationship to other diseases. Arthritis and Rheumatism 6 (Suppl.): 558–571 (1963).

    Article  PubMed  Google Scholar 

  • Tan, E.M.: Drug-induced autoimmune disease. Federation Proceedings 32: 1894–1897(1974).

    Google Scholar 

  • TenVeen, J.H. and Feltkamp, T.E.W.: Studies on drug-induced lupus erythematosus in mice. I. Drug induced antinuclear antibodies (ANA). Clinical and Experimental Immunology 11: 265–276 (1972).

    CAS  Google Scholar 

  • Winfeld, J.B. and Davis, J.S.IV.: Anti-DNA antibody in procainamide-induced lupus erythematosus. Determinations using DNA fractioned by methylated albumin-Kieselguhr chromatography. Arthritis and Rheumatism 17: 97–110 (1974).

    Google Scholar 

  • Winfield, J.B.; Koffler, D. and Kunkel, H.G.: Development of antibodies to ribonucleoprotein following short-term therapy with procainamide. Arthritis and Rheumatism 18: 531–534 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Worlledge, S.M.; Carstairs, K.C. and Dacie, J.V.: Autoimmune haemolytic anaemia associated with αmethyldopa therapy. Lancet 2: 135–139 (1966).

    Article  PubMed  CAS  Google Scholar 

  • Yamauchi, Y.; Litwin, A.; Adams, L.; Zimmer, H. and Hess, E.V.: Induction of antibodies to nuclear antigens in rabbits by immunization with hydralazine-human serum albumin conjugates. Journal of Clinical Investigation 56: 958–969 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Zingale, S.B.; Sánchez Avalos, J.C.; Andrada, J.A.; String, S.G. and Manni, J.A.: Appearance of anticoagulant factors and certain ‘autoimmune’ antibodies following antigenic stimulation with blood groups substances in patients with systemic lupus erythematosus. Arthritis and Rheumatism 6: 581–598 (1963).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology and Rheumatology, Institute Nacional de la Nutrición, Mexico 22, DF, Mexico

    Donato Alarcón-Segovia

Authors
  1. Donato Alarcón-Segovia
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alarcón-Segovia, D. Drug-Induced Antinuclear Antibodies and Lupus Syndromes. Drugs 12, 69–77 (1976). https://doi.org/10.2165/00003495-197612010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-197612010-00003

Keywords

Search

Navigation